🇺🇸 tenofovir disproxil fumarate/emtricitabine in United States
8 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 22 April 2025 – 22 April 2026
- Total reports: 8
Most-reported reactions
- Blood Creatine Phosphokinase Increased — 1 report (12.5%)
- Diarrhoea — 1 report (12.5%)
- Headache — 1 report (12.5%)
- Intracardiac Mass — 1 report (12.5%)
- Maternal Drugs Affecting Foetus — 1 report (12.5%)
- Renal Impairment — 1 report (12.5%)
- Stillbirth — 1 report (12.5%)
- Vomiting — 1 report (12.5%)
Other Infectious Disease / Virology approved in United States
Frequently asked questions
Is tenofovir disproxil fumarate/emtricitabine approved in United States?
tenofovir disproxil fumarate/emtricitabine does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for tenofovir disproxil fumarate/emtricitabine in United States?
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections is the originator. The local marketing authorisation holder may differ — check the official source linked above.